6CM
KLRS

683 Capital Management’s Kalaris Therapeutics KLRS Stock Holding History

683 Capital Management’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-45,000
Closed -$260K – 254
2026
Q1 		$260K Sell
45,000
-35,590
-44% -$316K 0.01% 212
2025
Q4 		$680K Buy
+80,590
New +$515K 0.03% 172
2024
Q1 		– Sell
-8,286
Closed -$130K – 269
2023
Q4 		$130K Buy
+8,286
New +$327K 0.01% 215

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

683 Capital Management's KLRS Position: Q2 2026 in Review

683 Capital Management sold out of Kalaris Therapeutics (KLRS) in Q2 2026, closing a stake of 45,000 shares — an estimated $260K sold.

683 Capital Management first reported a position in KLRS in Q4 2023 and held it in 3 quarters. The position peaked at $680K in Q4 2025. 57 funds tracked by Wall St. Rank hold KLRS as of Q2 2026.

  • 683 Capital Management reported no remaining Kalaris Therapeutics position as of Q2 2026 after selling out during the quarter.
  • 683 Capital Management sold 45,000 Kalaris Therapeutics shares in Q2 2026, an estimated $260K.
  • 683 Capital Management first reported a position in Kalaris Therapeutics in Q4 2023 and held it in 3 quarters.
  • 683 Capital Management's Kalaris Therapeutics position peaked at $680K in Q4 2025.
  • 57 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2026.

Based on 683 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.